GWAS studies have repeatedly confirmed that TRIB1 gene polymorphisms were associated with dyslipidemia [22–25], and several studies had shown that TRIB1 gene variants can increase the risk of CHD [26, 27]. This evidence concerns the gene TRIB1 and metabolic syndrome.